Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 07ANKARA293, BEST YEAR EVER: TURKEY IMPORTANT MARKET FOR U.S. PHRMA

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #07ANKARA293.
Reference ID Created Released Classification Origin
07ANKARA293 2007-02-12 12:23 2011-08-24 01:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Ankara
null
Tim W Hayes  03/02/2007 04:29:05 PM  From  DB/Inbox:  Tim W Hayes

Cable 
Text:                                                                      
                                                                           
      
UNCLAS    SENSITIVE     ANKARA 00293

SIPDIS
CX:
    ACTION: ECON
    INFO:   PA RAO FAS MGT PMA FCS POL DCM AMB CONS

DISSEMINATION: ECON /1
CHARGE: PROG

APPROVED: ECON:TGOLDBERGER
DRAFTED: ECON:RKIMBRELL
CLEARED: IST:SSO, FCS:JF, ECON: AS, AS

VZCZCAYI125
PP RUEHC RUCPDOC RUEHIT RUEHDA RUEHBS RUEATRS
DE RUEHAK #0293/01 0431223
ZNR UUUUU ZZH
P 121223Z FEB 07
FM AMEMBASSY ANKARA
TO RUEHC/SECSTATE WASHDC PRIORITY 0916
INFO RUCPDOC/USDOC WASHDC PRIORITY
RUEHIT/AMCONSUL ISTANBUL 2099
RUEHDA/AMCONSUL ADANA 1640
RUEHBS/USEU BRUSSELS
RUEATRS/DEPT OF TREASURY WASHDC
UNCLAS SECTION 01 OF 02 ANKARA 000293 
 
SIPDIS 
 
DEPT PLEASE PASS USTR FOR LERRION/BPEUK 
DEPT PLEASE PASS USPTO FOR JO ELLEN URBAN 
USDOC FOR ITA/MAC/CRUSNAK 
USEU FOR JULIE NUTTER AND USTR 
TREASURY FOR JONATHAN ROSE 
 
SENSITIVE 
SIPDIS 
 
E.O. 12958: N/A 
TAGS: ETRD KIPR USTR EUN TU
SUBJECT: BEST YEAR EVER: TURKEY IMPORTANT MARKET FOR U.S. PHRMA 
COMPANIES 
 
 
SENSITIVE BUT UNCLASSIFIED. NOT FOR INTERNET DISTRIBUTION. 
 
Ref: (A) Ankara 5335 and previous 
 
1. (SBU) Summary:  Turkey currently represents the 14th largest 
market in the world in terms of pharmaceutical sales, and it is on 
track to grow to the 10th largest by 2009.  The size of the market 
comes from volume and not from the pricing of pharmaceuticals, which 
PhRMA company representatives complain are much too low.  In 
addition to ongoing IPR issues (reftels), PhRMA companies in Turkey 
worry about the length of time it takes to receive marketing 
approval and to get their products included on the list of drugs 
authorized for reimbursement under the state-run health insurance 
scheme, which accounts for 90% of health care spending in the 
country. 
 
-------------------------------------------- 
14TH LARGEST MARKET FOR PHARMACEUTICAL SALES 
-------------------------------------------- 
 
2. (SBU) Turkey is an important growth market for research-based 
pharmaceutical companies.  In 2005, pharmaceutical sales in Turkey 
amounted to approximately $6.5 billion, 50-65% of which went to 
innovative U.S. and European companies.  According to the innovative 
companies, Turkey represents the 14th largest market in the world 
for pharmaceutical sales, and it is on track to grow to the 10th 
largest by 2009. 
 
3. (SBU) Given low per capita healthcare spending, the innovative 
companies believe there is tremendous headroom for growth. 
According to OECD data, Turkey currently spends $580 per capita on 
healthcare, 25% of which is spent on pharmaceuticals.  This is much 
lower than the average for EU countries ($2,100) and the U.S. 
($6,102).  Turkey's state-run healthcare system provides 90% of 
medical care, including treatment at state (public) hospitals, 
80-90% compensation for drug expenses, and insurance against 
job-related injuries and illnesses.  Only about 1 percent of 
Turkey's population utilizes private insurance, which allows access 
to better healthcare services in private hospitals and labs with 
small co-payments for medical care and prescriptions. 
 
----------------------- 
LOW PRICES, HIGH VOLUME 
----------------------- 
 
4. (SBU) Pharmaceutical pricing in Turkey continues to be an issue 
of importance to innovative pharmaceutical companies.  According to 
AiFD (Turkey's version of PhRMA) General Manager Engin Guner, prices 
in Turkey are currently 17% lower than the cheapest countries in 
Europe.  Company representatives tell us it is the volume of 
consumption that keeps Turkish market as one of the largest in the 
world, not the price of the products.  Eli Lilly representatives 
told us that if Turkey implemented a pricing system similar to 
Germany, their profits would increase by approximately $240 million 
each year; using Hungary's prices, profits would increase by $140 
million. 
 
------------------------------------------- 
SLOW APPROVALS, HEALTHCARE SPENDING REFORMS 
------------------------------------------- 
 
5. (SBU) As their main concern, U.S. company representatives point 
to the slow approval process for new products to be registered and 
authorized for reimbursement under the state insurance scheme. EU 
directives require that new pharmaceutical applications be reviewed 
within 210 calendar days.  The Turkish MOH, however, previously 
interpreted this as 210 business days and stopped the clock whenever 
additional information was requested from the companies.  However, 
this is just the first step.  Once a product is registered, the wait 
for it to be reviewed and approved for inclusion in the socialized 
healthcare system can take another year.  Often, after enduring 
years of waiting, innovative companies have received a refusal 
notification from the Turkish MOH without an explanation.  AiFD has 
been working with the new Social Security Institution (SGK), which 
is responsible for developing the drug reimbursement schedule, to 
reform the system to review drugs within three months, provide clear 
reasons for refusals, and to create an appeals process for refusals. 
 According to Guner, the new President of SGK has been receptive to 
their proposals and AiFD is optimistic that these changes will be 
implemented. 
 
6. (SBU) PhRMA company representatives have also expressed concern 
about the recently approved agreement between Turkey and the IMF to 
limit the growth of government health spending.  The GOT agreed with 
the Fund to reduce the reimbursable margin between the cheapest and 
most expensive reimbursed drugs in a given bioequivalence group from 
22 to 20% and to reduce the price of generic drugs from 80% of the 
original price down to a maximum of 72%.  The GOT also plans to 
increase the number of comparator countries used to determine the 
reference prices for pharmaceuticals (which could exacerbate the 
already low prices).  Finally, the GOT agreed to train physicians in 
the appropriate use of drugs, particularly antibiotics.  The 
companies feel that innovative pharmaceutical purchases are bearing 
an unfair share of spending adjustments (generic products are not so 
affected) and that Turkish patients are being denied access to the 
best medicines as a result. 
 
---------------------- 
AND SPEAKING OF IPR... 
---------------------- 
 
7. (SBU) Lest we forget, PhRMA companies in Turkey are still trying 
to resolve ongoing data-exclusivity (DE) issues (ref A).  While the 
EU and the USG regularly weigh in on the issue, Turkey's MOH is 
exhibiting marked fatigue.  Turkey's generics manufacturers, who 
historically have been well-connected politically, consider the DE 
problem solved.  Representatives of the Pharmaceutical Manufacturing 
Organization in Turkey (which represents generics manufacturers) 
told us that the DE issue was resolved with the new legislation. 
They cautioned that the organization's role will change from 
"protecting" generics manufacturers' rights to license molecules by 
working with the government to fighting in the courts "outrageous" 
claims to data protection that overstep both Turkish and EU 
regulations.  They believe that generics and innovative companies 
can begin to work together, however, on the pricing issue. 
 
----------------------------------- 
SITUATION NOT PERFECT BUT LUCRATIVE 
----------------------------------- 
 
8. (SBU) Comment:  While the situation in Turkey for U.S. innovative 
pharmaceutical companies is certainly not perfect, Turkey has been 
and should continue to be a lucrative market. Since the GOT is their 
largest customer in Turkey, it is understandable that PhRMA 
companies prefer the USG and the EU to take the lead in pushing for 
improved IPR protection and the GOT's compliance with its 
international obligations.  The threat of reprisal is real, and with 
the IFI's pressuring Turkey to cut its public healthcare costs, 
continued dialogue on this issue will be needed to ensure that these 
cuts are evenly distributed between Turkey's domestic generics 
manufacturers and the multinationals operating here. 
 
WILSON